SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Syndax Pharmaceuticals is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has supportive analyst sentiment and favorable options positioning, but the current technical setup is only mixed, there is no fresh news catalyst, and the proprietary signals are absent. At a pre-market price of 19.46, I would not call this an immediate buy; the better call is to hold and wait for a clearer trend or a stronger catalyst.
SNDX is in a mildly constructive but not decisive technical position. MACD histogram is positive and expanding, which supports short-term momentum improvement. RSI_6 at 42.57 is neutral-to-weak, showing the stock is not oversold enough to be an obvious bargain. Moving averages are converging, which usually signals indecision rather than a confirmed trend. Key levels: pivot 20.035, resistance 20.891/21.419, support 19.179/18.651. The pre-market price of 19.46 sits just above first support but below the pivot, so the chart suggests a neutral setup rather than an immediate breakout entry.
Analysts remain broadly bullish, with multiple Buy/Overweight ratings and mostly high price targets. Recent commentary is constructive on Revuforj commercialization, Niktimvo growth, and longer-term upside from the IPF-related pipeline. Goldman also highlighted increased peak sales estimates for axatilimab in IPF, which supports long-term upside potential. Options positioning is bullish, and the stock has no negative news flow in the last week.
No news in the recent week means there is no immediate event-driven catalyst. Analyst price targets were mixed recently, with some firms lowering targets after Q1 results due to revenue misses. The stock is also below its pivot level and the RSI is not showing strong upside momentum. Trading-pattern analysis suggests near-term downside bias over the next week and month. AI Stock Picker and SwingMax both show no active signal today.
Latest quarter data was not available because the financial snapshot returned an error. Based on the analyst notes, Q1 results were mixed: Revuforj revenue missed expectations in part because about 50% of KMT2A patients went to transplant, while NPM1 patient additions were growing nicely. The current quarter referenced in the analyst commentary is Q1 2026, and the market appears focused on whether post-transplant maintenance can restore revenue growth over time.
Wall Street is still positive overall. Recent ratings were mostly Buy, Overweight, or Outperform, with price targets ranging roughly from $37 to $57. The trend is mixed but constructive: UBS and Jefferies trimmed targets slightly, Stifel turned more positive and raised its target, Barclays raised its target, and Citi remains the most bullish. The pros view is that Revuforj is already winning commercially and the pipeline offers upside, while the cons view is that recent sales misses show execution is not yet perfect and some of the longer-term value still depends on pipeline success. No recent politician, influencer, or congress trading activity was reported, and hedge fund/insider trading trends are neutral.
